目的 分析2017年1月—2019年12月天津市腫瘤醫(yī)院（天津醫(yī)科大學(xué)腫瘤醫(yī)院）抗腫瘤分子靶向藥使用情況，為臨床合理用藥及抗腫瘤新藥研發(fā)提供參考。方法 收集天津市腫瘤醫(yī)院2017年1月—2019年12月期間抗腫瘤分子靶向藥品種/品規(guī)數(shù)、使用金額、在抗腫瘤藥使用金額中的構(gòu)成比，并對(duì)用藥頻度（DDDs）、限定日費(fèi)用（DDC）及排序比（B/A）進(jìn)行回顧性分析。結(jié)果 2017—2019年，本院抗腫瘤分子靶向藥品由11種增至30余種；使用金額及在抗腫瘤藥使用金額中的構(gòu)成比呈逐年快速增長(zhǎng)趨勢(shì)，3年來(lái)使用金額由0.28億元增長(zhǎng)至3.65億元，增加了12倍多，構(gòu)成比從9.31%增至41.57%；各抗腫瘤分子靶向藥DDDs也大幅增加，其中以貝伐珠單抗、曲妥珠單抗增幅居前列；而DDC逐年下降，降幅大于25%，隨之，多數(shù)藥物B/A值逐漸接近或大于1，使用金額與DDDs趨于一致。結(jié)論 本院抗腫瘤分子靶向藥物使用與本院收治患者人群特征和指南治療方案基本一致，使用基本合理；醫(yī)改新政策出臺(tái)，分子靶向藥納入醫(yī)保，藥品價(jià)格大幅下降，患者治療費(fèi)用降低，使得更多患者的治療與國(guó)際接軌，提高了治療的有效率，成為新醫(yī)改政策的直接受益者。

Objective To investigate the utilization of molecular targeted antineoplastic drugs in Tianjin Cancer Hospital from 2017 to 2019, and provide reference for rational clinical uses and antitumor drugs research and development. Methods By retrospective survey, the utilization of molecular targeted antineoplastic drugs in Tianjin Cancer Hospital during 2017—2019 was analyzed in terms of consuption sum, DDDs, DDC and sorting ratio (B/A). Results The categories of molecular targeted antineoplastic drugs increased significantly year by year, the categories increased from 11 varieties in 2017 to 30 varieties in 2019; and quantities increased from 0.28 billion in 2017 to 3.65 billion in 2019, rising nearly 12-fold from 2017 to 2019; as well as the proportions of that to antineoplastic drugs, it increased from 9.31% to 41.57%, The DDDs of molecular targeted antineoplastic drugs increased significantly, Bevacizumab, Sorafenib and Trastuzumab took up the top growth list; the B/A values of most drugs were well synchronized. And the DDC values of molecular targeted antineoplastic drugs were reduced after due to the health insurance, Imatinib, Cetuximab, Gefitinib etc. 9 categories reduced by more than 50%. Conclusion The applications of molecular targeted antineoplastic drugs are well synchronize with the characteristics of patients and guideline in Tianjin Cancer Hospital, the applications are basically rational; the prices of molecular targeted antineoplastic drugs are reduced due to the health insurance, molecular targeted antineoplastic drugs incorporated into Medical Insurance Policy, which is helpful to reduce the health care burdens of residents. The patients can follow the international first-line treatment, and become the direct beneficiary of health reform.

R979.1